SRPT Sarepta Therapeutics Inc

$20.22

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 8/22/2025

About Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.

Website: https://www.sarepta.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
873303
Address
215 FIRST STREET, SUITE 415, CAMBRIDGE, MA, US
Valuation
Market Cap
$5.22B
P/E Ratio
22.99
PEG Ratio
159.25
Price to Book
3.42
Performance
EPS
$2.34
Dividend Yield
Profit Margin
12.40%
ROE
19.70%
Technicals
50D MA
$85.80
200D MA
$117.82
52W High
$173.25
52W Low
$48.01
Fundamentals
Shares Outstanding
97M
Target Price
$154.08
Beta
0.92

SRPT EPS Estimates vs Actual

Estimated
Actual

SRPT News & Sentiment

Aug 22, 2025 • Benzinga NEUTRAL
SRPT 3-DAY DEADLINE ALERT: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN FRANCISCO, Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- A securities class-action lawsuit is underway against Sarepta Therapeutics SRPT, triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit alleges that Sarepta misled investors by presenting ...
Aug 22, 2025 • Benzinga NEUTRAL
SRPT FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 25 Deadline in Securities Class Action - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. SRPT between June 22, 2023 and June 24, 2025, both dates inclusive ( the "Class Period" ) , of the important August 25, 2025 ...
Aug 21, 2025 • Benzinga NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ( "Sarepta" or the "Company" ) SRPT. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ( or ...
Aug 21, 2025 • Benzinga SOMEWHAT-BULLISH
What's Going On With Sarepta Shares Thursday? - Sarepta Therapeutics ( NASDAQ:SRPT )
Sarepta swaps $700 million of 2027 notes for $602 million of new 2030 notes, stock, and cash. The new notes convert at $60 per share, a 191.5% premium to the last close of $20.58. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here →
Aug 21, 2025 • Benzinga NEUTRAL
SRPT DEADLINE NOTICE: Sarepta Therapeutics, Inc. Investors are Notified of the August 25 Class Action Deadline -- Contact BFA Law if You Suffered Losses ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
Aug 21, 2025 • Benzinga NEUTRAL
INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN DIEGO, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. SRPT securities between June 22, 2023 and June 24, 2025, inclusive ( the "Class Period" ) , have until Monday, August 25, 2025 to seek appointment ...
Sentiment Snapshot

Average Sentiment Score:

0.095
50 articles with scored sentiment

Overall Sentiment:

Neutral

SRPT Reported Earnings

Apr 29, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.00
  • Whisper:
  • Surprise %: 0.0%
Feb 26, 2025
Dec 31, 2024 (Pre market)
-0.16 Surprise
  • Reported EPS: $1.90
  • Estimate: $2.06
  • Whisper:
  • Surprise %: -7.8%
Nov 06, 2024
Sep 30, 2024 (Post market)
0.47 Surprise
  • Reported EPS: $0.34
  • Estimate: $-0.13
  • Whisper:
  • Surprise %: 361.5%
Aug 07, 2024
Jun 30, 2024 (Post market)
0.06 Surprise
  • Reported EPS: $0.07
  • Estimate: $0.01
  • Whisper:
  • Surprise %: 600.0%
May 01, 2024
Mar 31, 2024 (Post market)
0.44 Surprise
  • Reported EPS: $0.37
  • Estimate: $-0.07
  • Whisper:
  • Surprise %: 628.6%
Feb 28, 2024
Dec 31, 2023 (Post market)
0.46 Surprise
  • Reported EPS: $0.47
  • Estimate: $0.01
  • Whisper:
  • Surprise %: 4600.0%
Nov 01, 2023
Sep 30, 2023 (Post market)
0.77 Surprise
  • Reported EPS: $-0.46
  • Estimate: $-1.23
  • Whisper:
  • Surprise %: 62.6%
Aug 02, 2023
Jun 30, 2023 (Post market)
1.51 Surprise
  • Reported EPS: $-0.27
  • Estimate: $-1.78
  • Whisper:
  • Surprise %: 84.8%
May 02, 2023
Mar 31, 2023 (Post market)
-4.48 Surprise
  • Reported EPS: $-5.86
  • Estimate: $-1.38
  • Whisper:
  • Surprise %: -324.6%

Financials